SYNLOGIC, INC. Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted
SYNLOGIC, INC. (SYBX) reported Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted of 1.64 million shares for the 3-month period ending 2017-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted · last filed 2018-05-15
- SYNLOGIC, INC. weighted average number of limited partnership and general partnership unit outstanding, basic and diluted for the quarter ending 2017-03-31 was 1.64M shares.
- SYNLOGIC, INC. weighted average number of limited partnership and general partnership unit outstanding, basic and diluted for the quarter ending 2016-09-30 was 1.59M shares.
- SYNLOGIC, INC. weighted average number of limited partnership and general partnership unit outstanding, basic and diluted for fiscal 2016 was 1.58M shares.
| Period end | Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted 3 month | Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted 9 month | Weighted Average Number of Limited Partnership and General Partnership Unit Outstanding, Basic and Diluted 12 month |
|---|---|---|---|
| 2017-03-31 | 1.64M shares 10-Q · filed 2018-05-15 | ||
| 2016-12-31 | 1.58M shares 10-K · filed 2018-03-20 | ||
| 2016-09-30 | 1.59M shares 10-Q · filed 2017-11-13 | 1.54M shares 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |